Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

32.95 +11.52 (+53.76%)

Streaming Delayed Price Updated: 1:09 PM EDT, Aug 18, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	17,259,643
Open	29.91
Bid (Size)	32.93 (200)
Ask (Size)	32.97 (100)
Prev. Close	21.43
Today's Range	28.00 - 33.26
52wk Range	7.630 - 24.60
Shares Outstanding	67,176,067
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Amylyx Phase III Avexitide Trial Cuts Severe Hypoglycemic Events 55% ↗

Today 10:04 EDT

Amylyx Pharmaceuticals (NASDAQ:AMLX) said its Phase III LUCIDITY trial of avexitide met its primary endpoint, reducing the composite rate of clinically significant hypoglycemic events by 55% versus...

Via MarketBeat

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

Today 8:06 EDT

Gainers Amylyx Pharmaceuticals (NASDAQ:AMLX) stock increased by 27.5% to $27.32 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.3 billion. bioAffinity...

Via Benzinga

Performance

YTD	+188.5%	+188.5%
1 Month	+88.8%	+88.8%
3 Month	+156.2%	+156.2%
6 Month	+133.2%	+133.2%
1 Year	+312.4%	+312.4%

More News

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

Today 7:00 EDT

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals (NASDAQ:AMLX) Misses on Q2 Bottom Line as LUCIDITY Readout Looms ↗

August 06, 2026

Via Chartmill

Amylyx Pharmaceuticals (NASDAQ:AMLX) Q1 Loss Slightly Wider Than Expected as All Eyes Turn to Q3 Avexitide Trial Data ↗

May 07, 2026

Via Chartmill

Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026

August 17, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx (AMLX) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Via The Motley Fool

Amylyx Pharmaceuticals Q2 Earnings Call Highlights ↗

August 06, 2026

Via MarketBeat

Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 06, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

August 03, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026

June 23, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape ↗

June 10, 2026

Via MarketBeat

Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026

June 08, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

What to Know About This Fund's $10 Million Bet on Gold Miners ↗

May 24, 2026

Via The Motley Fool

Amylyx Stock: Why the Full Pipeline Story Matters ↗

May 24, 2026

Via MarketBeat

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗

May 19, 2026

Via The Motley Fool

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗

May 19, 2026

Via The Motley Fool

Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation

May 15, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus ↗

May 14, 2026

Via MarketBeat

Amylyx (AMLX) Q1 2026 Earnings Transcript ↗

May 08, 2026

Via The Motley Fool

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

May 07, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

May 06, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

May 05, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

April 30, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

April 08, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Frequently Asked Questions

Is Amylyx Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Amylyx Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Amylyx Pharmaceuticals, Inc. - Common Stock trade on?

Amylyx Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock is AMLX on the Nasdaq Stock Market

What is the current price of Amylyx Pharmaceuticals, Inc. - Common Stock?

The current price of Amylyx Pharmaceuticals, Inc. - Common Stock is 32.95

When was Amylyx Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Amylyx Pharmaceuticals, Inc. - Common Stock was at 08/18/26 01:09 PM ET

What is the market capitalization of Amylyx Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Amylyx Pharmaceuticals, Inc. - Common Stock is 2.21B

How many shares of Amylyx Pharmaceuticals, Inc. - Common Stock are outstanding?

Amylyx Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.